Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy. Farmeconomia. Health economics and therapeutic pathways, [S. l.], v. 18, n. 1, 2017. DOI: 10.7175/fe.v18i1.1321. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/1321. Acesso em: 28 oct. 2025.